Bimatoprost SR is a medication used in this clinical trial to help lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. This medication is designed to be a long-lasting treatment option for those who have difficulty managing their condition with regular eye drops, either because they cannot tolerate them or have trouble sticking to their treatment schedule. Bimatoprost SR is administered in a way that allows it to gradually release the active ingredient over time, providing a sustained effect in reducing eye pressure.

Open-Angle Glaucoma – This is a chronic eye condition where the drainage angle formed by the cornea and iris remains open, but the trabecular meshwork is partially blocked. This blockage leads to a gradual increase in eye pressure, which can damage the optic nerve. Over time, this damage can lead to vision loss, starting with peripheral vision. The progression is typically slow and painless, making it difficult to detect in early stages without regular eye exams. As the disease advances, central vision may also be affected.

Ocular Hypertension – This condition is characterized by higher than normal pressure inside the eye, known as intraocular pressure (IOP). Unlike glaucoma, ocular hypertension does not cause any noticeable damage to the optic nerve or vision loss. However, it is considered a risk factor for developing glaucoma in the future. The condition progresses without symptoms, so regular monitoring by an eye care professional is essential. It is important to differentiate it from glaucoma, as the management and implications can differ.